University of California

Boston Pharmaceuticals To Present New Phase 2a Data From Investigational BOS-580 NASH Program at AASLD The Liver Meeting® 2023

Retrieved on: 
Tuesday, November 7, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Liver injury, American Association for the Study of Liver Diseases, Biomarker, Hepatology, University of California, Medication, Liver, Diabetes, Fibrosis, Hepatitis, Metabolism, FGF21, Liver disease, Disease, NASH, Division, Doctor of Pharmacy, Fatty liver disease, University, AASLD, Pharmaceutical industry, Medical imaging, Patient, Gastroenterology

Boston Pharmaceuticals , a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH), at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Key Points: 
  • Boston Pharmaceuticals , a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH), at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place November 10-14, 2023, in Boston.
  • BOS-580 is a long-acting, highly engineered fibroblast growth factor 21 (FGF21) analog administered via a once-monthly subcutaneous injection.
  • BOS-580 is designed to reduce liver fat content, liver inflammation as evidenced by biomarkers of liver injury and fibrosis and improve metabolism as evidenced by the impact on metabolic biomarkers in patients with NASH.
  • We are especially pleased that our presentation on the impact of BOS-580 treatment in subgroups of NASH patients who also have diabetes was designated as a poster of distinction by AASLD, placing it among the foremost presentations at this year’s meeting,” stated Sophie Kornowski, PharmD, CEO of Boston Pharmaceuticals.

Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Medical Devices, Health, Clinical Trials, Medical Supplies, DCB, University of California, RCT, Yolo Bypass, Clinical trial, Dess, University, Safety, Randomized controlled trial, Medtronic, Veterinary medicine

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial will be presented at the upcoming 50th Annual VEITH Symposium in New York, New York.

Key Points: 
  • Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial will be presented at the upcoming 50th Annual VEITH Symposium in New York, New York.
  • Dr. Peter A. Schneider, Professor of Surgery at University of California, San Francisco and Member of the TRANSCEND Trial Steering Committee, will present the TRANSCEND trial’s safety and efficacy data through 36 months as part of a November 15, 2023 session focused on randomized controlled trial (RCT) updates on new developments in drug coated balloons (DCBs) and drug eluting stents (DESs).
  • Preliminary schedule details are provided below.
  • 3-Year Results of A RCT Comparing SurVeil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating FemPop Lesions: From the TRANSCEND Trial

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Health, Science, Research, Clinical Trials, Patient, Lupus nephritis, Week, American College, CNI, EGFR, Human, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., TAC, AURORA, Safety, University of California, CSA, VCS, Lupus, Society, Mouse, Acute kidney injury, Ciclosporin, Division, Clinical trial, Efficacy, Physiology, Biopsy, MMF, University, Tacrolimus, Glucocorticoid, ACR, Conditional sentence, Proteinuria, Lithium toxicity, Pharmaceutical industry, Rheumatology, Black, ALMS, Aurinia, Medicine, UPCR, LN

Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.

Key Points: 
  • Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.
  • In AURORA 1, patients received LUPKYNIS® 23.7 mg BID in combination with MMF (target dose 2 g/day) and oral glucocorticoids (starting dose of 25 mg/day tapered to 2.5 mg/day by Week 16).
  • The data showed an improved safety profile over the first six months of treatment with LUPKYNIS® in combination with low-dose glucocorticoids and lower-dose MMF without compromising efficacy.
  • Additional data assessed the disposition of cyclosporine (CSA), tacrolimus (TAC), and voclosporin (VCS) in mouse kidneys relative to its systemic drug exposure.

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

Retrieved on: 
Thursday, November 2, 2023
Transplant, Labcorp, UCSF, American Association for the Study of Liver Diseases, BMI, Hepatology, MD, University of California, MBA, ACLF, PBC, Gubra, NAS, Poster, Division, NASH, GAN, Biopsy, University, CET, Primary biliary cholangitis, FACP, Ipsen, Patient, Abstract, Liver support system, IQVIA, AASLD, Medical device, Pharmaceutical industry, Medical imaging, Euronext, Gastroenterology

Participants include study investigators, principal investigators and other healthcare professionals from the US, France, Germany and the UK.

Key Points: 
  • Participants include study investigators, principal investigators and other healthcare professionals from the US, France, Germany and the UK.
  • Two Patient Advocacy Council sessions will be held on Saturday November 11, 2023.
  • Participants in this event include Dr. Jennifer Lai (MD, MBA, FACP) and the Global Liver Institute.
  • GENFIT will present new data on its NASH diagnostics technology, including:
    The impact of BMI on NIS2+™ and established non-invasive tests for the evaluation of non-alcoholic liver disease (15’ Oral Presentation #238, Pr.

Tillys Executives Join Tilly’s Life Center Board of Directors

Retrieved on: 
Monday, November 6, 2023
Philanthropy, Foundation, Omni, Digital, University of California, NYSE, California Polytechnic State University, San Luis Obispo, Organization, Senior, Wet Seal, Villanova University, Growth, Taco Bell, Business administration, PacSun, Executive, University, Performance, TLC, Management, Tillys, Science, Western Washington University

Today, youth-focused empowerment nonprofit Tilly’s Life Center (TLC) is proud to announce that it has appointed four c-level Tillys executives to its board of directors.

Key Points: 
  • Today, youth-focused empowerment nonprofit Tilly’s Life Center (TLC) is proud to announce that it has appointed four c-level Tillys executives to its board of directors.
  • This includes Tilly’s, Inc. (NYSE: TLYS, "Tillys") President and CEO Edmond Thomas, Executive Vice President and Chief Merchandising Officer Laura Janney, Executive Vice President and Chief Financial Officer Michael Henry, and Chief Digital Officer Jonathan Kosoff.
  • Laura Janney - Executive Vice President, Chief Merchandising Officer
    Laura Janney joined Tillys as the Executive Vice President, Chief Merchandising Officer in April 2023.
  • Michael Henry - Executive Vice President, Chief Financial Officer
    Michael Henry has served as Tillys Executive Vice President, Chief Financial Officer since September 2019, following his service as Tillys Vice President, Chief Financial Officer from May 2015 to September 2019.

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

Retrieved on: 
Thursday, November 2, 2023
Research, Thought Leadership, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPO, Pharmacyclics, Catalent, Alder, Therapy, Hematology, Nutcracker, MBS, Head, CMC, Seagen, Lundbeck, University of California, Acquisition, PTK7, Protein, Economics, Lundbeck Seattle Biopharmaceuticals, Yale University, Immunotherapy, Growth, SITC, ADC, Division, University, Biology, Amgen, Baxter International, Internal medicine, Merrill (company), Business, Keck Graduate Institute, Society for Immunotherapy of Cancer, Genentech, Society, Cancer, Seattle, University of Southern California, Coronavirus Scientific Advisory Board, Fine chemical, Management, Biochemistry, Proteolix, Chiron, Spacecraft, Western Washington University

We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.

Key Points: 
  • We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.
  • In addition, as chair of our Scientific Advisory Board, Lori brings decades of clinical thought-leadership and strategic product development experience in ADCs.
  • We look forward to working alongside them.”
    ProfoundBio also announced additional changes to the company's executive team.
  • Co-founders Tae Han and Xiao Shang will take on the roles of chief strategy officer and head of CMC, respectively.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Retrieved on: 
Wednesday, November 1, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Survival, Patient, Colitis, Nephritis, Cholangiocarcinoma, Incidence, Hypothyroidism, Pneumonitis, NYSE, Food, Progression-free survival, Fatigue, Medicine, Itch, DOR, AST, Pembrolizumab, Cisplatin, Head, Gastrointestinal cancer, MRK, PFS, Fever, University of California, Bile, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV disease progression rates, Administration, Rash, Disease, Ascending cholangitis, Merck & Co., Risk, Immunotherapy, ORR, University, Anemia, RECIST, BTC, Hepatitis, Biliary tract, Lymphocyte, ALT, OS, Death, Toxicity, Hematopoietic stem cell transplantation, CI, Pharmaceutical industry, Vaccine, Merck

Median OS was 12.7 months (95% CI, 11.5-13.6) for KEYTRUDA plus chemotherapy versus 10.9 months (95% CI, 9.9-11.6) for chemotherapy alone.

Key Points: 
  • Median OS was 12.7 months (95% CI, 11.5-13.6) for KEYTRUDA plus chemotherapy versus 10.9 months (95% CI, 9.9-11.6) for chemotherapy alone.
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • For gemcitabine, treatment could be continued beyond eight cycles, while for cisplatin, treatment could be administered for a maximum of eight cycles.
  • There was a difference of ≥5% incidence in laboratory abnormalities between patients who received KEYTRUDA plus chemotherapy versus placebo plus chemotherapy for decreased lymphocytes (69% vs. 61%).

POLARIS[AR] RECEIVES CLEARANCE FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR STELLAR KNEE

Retrieved on: 
Friday, November 3, 2023
Knee, FDA, Standard of care, Columbia University Irving Medical Center, Food, Surgeon, Orthopedic surgery, Elective surgery, University of California, Regulation of tobacco by the U.S. Food and Drug Administration, Software, Environment, Mixed reality, University, Columbia University, Algorithm, Augmented reality, Robotics, Associate, Medical device, Medical imaging

MIAMI, Nov. 3, 2023 /PRNewswire/ -- POLARISAR is pleased to announce today that their STELLAR Knee has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MIAMI, Nov. 3, 2023 /PRNewswire/ -- POLARISAR is pleased to announce today that their STELLAR Knee has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
  • STELLAR Knee is the first clearance for POLARISAR, a company focused on creating a new category in Mixed Reality surgical guidance.
  • The STELLAR Knee workflow is open and available to be utilized across all total knee replacement implant systems.
  • STELLAR Knee not only impacts the surgeon and the patient, but also empowers healthcare providers to change the standard of care."

Anheuser-Busch, MADD, and Uber Partner with Hensley Beverage Company of Arizona to Encourage 21+ Fans to 'Decide to Ride' by Planning Ahead for Sober Rides on Game Days

Retrieved on: 
Thursday, November 2, 2023
University, MADD, Drinking, Legal drinking age, Anheuser-Busch, Arizona Wildcats hockey, Family, Policy, Mothers Against Drunk Driving, University of California, Research, Friends, University of Arizona, Uber, Hensley & Co., Norm (mathematics), Student, Wildcat, Culture, Mother, Safety, Foreign policy, Arizona Wildcats, Arizona House of Representatives, Beer, Ridesharing

ST. LOUIS, Nov. 2, 2023 /PRNewswire/ -- The country's leading brewer, Anheuser-Busch, the nation's largest drunk driving victim services and advocacy nonprofit, Mothers Against Drunk Driving (MADD), and ridesharing platform, Uber, are bringing their first-of-its-kind coalition to college communities this fall. As a part of the next phase of the Decide to Ride campaign, the coalition is teaming up with Anheuser-Busch wholesaler partner Hensley Beverage Company to help combat drunk driving during the Arizona Wildcats' 2023 football season. 

Key Points: 
  • This joint effort will meet 21+ fans in the stands to raise awareness and promote road safety by providing educational and ridesharing opportunities, including some locally available discounts on Uber rides.
  • To ensure a future with more cheers for all, it's imperative that we help college football fans get home safely.
  • "To showcase our commitment, we're teaming up with Anheuser-Busch, MADD, and Uber to promote the Decide to Ride pledge.
  • Ahead of the fall football season, we want to make it easy for everyone to Decide to Ride."

Class of 2024 Tillman Scholar Applications Open Today

Retrieved on: 
Wednesday, November 1, 2023
American Service-Members' Protection Act, PTF, Policy, Education, Arizona State University, Syracuse University, University of South Florida, Pat Tillman Foundation, American University School of International Service, Gonzaga University, University of Missouri System, Georgetown University, University of Oklahoma, George Washington University, University of Maryland, College Park, Florida A&M University, University of California, Spouse, University of Arizona, Texas A&M University, Medicine, Ohio State University, University of Minnesota, University, Columbia University, Culture, Indiana University, Book, Health insurance, Management, Nursing, Veteran

CHICAGO, Nov. 1, 2023 /PRNewswire/ -- Today, the Pat Tillman Foundation opened the annual application process for the Tillman Scholars program. Eligible military service members, veterans and spouses can apply to join the 2024 class of Tillman Scholars until Friday, February 1, 2024, at 11:59 p.m. PT.

Key Points: 
  • Eligible military service members, veterans and spouses can apply to join the 2024 class of Tillman Scholars until Friday, February 1, 2024, at 11:59 p.m. PT.
  • "As we begin to celebrate 20 years as the Pat Tillman Foundation, we could not be more thrilled to open the process of identifying the next generation of leaders we call Tillman Scholars," says Marie Tillman-Shenton, board chair and co-founder.
  • "The 60 individuals we identify as our 2024 class of Tillman Scholars will not just receive a scholarship, but a lifetime investment in their future as the leaders of tomorrow," says Katherine Steele, Programs Director and 2014 Tillman Scholar.
  • University Partners are established on an invitation-only basis, and help identify and select qualified Tillman Scholar candidates on their campus and help grow the Tillman Scholar community.